多廿烷醇在老年心血管病患者中的多效性分析被引量：2

The multi effects of policosanol on cardiovascular diseases in the eldly patients

下载PDF

导出

摘要目的研究多廿烷醇在老年心血管疾病患者中调脂作用外的多效性作用。方法入选老年血脂异常患者共294例,随机将入选患者分4组,多廿烷醇20 mg组(A组,n=64)、多廿烷醇10 mg组(B组,n=72)、阿托伐他汀20 mg组(C组,n=91)、多廿烷醇10 mg+阿托伐他汀20 mg组(D组,n=62)。所有患者分别于试验开始前、试验第12周、24周、52周时,测定其血小板计数、血小板聚集率、循环内皮细胞(CECs)计数、超敏C反应蛋白(hs-CRP)、颈动脉内膜中层厚度(IMT)等。结果 A组治疗后二磷酸腺苷(ADP)诱导的血小板聚集率较治疗前有较明显降低[(48.79±20.29)%比(40.37±23.56)%],差异有统计学意义(P<0.05),但花生四烯酸(AA)诱导的血小板聚集率差异无统计学意义。B组、C组和D组的AA及ADP诱导的血小板聚集率均差异无统计学意义。各组CECs、hs-CRP、同型半胱氨酸治疗后均较治疗前降低,差异有统计学意义(P<0.05),但颈动脉IMT在各组治疗前后均差异无统计学意义。结论多廿烷醇除可调节血脂水平外,还有一定的改善内皮细胞功能及抗动脉粥样硬化作用。 Objective To comparatively observe Policosanol’ s multi effects beyond lipid lowering in the eld-erlypatientswithcardiovasculardiseases.Methods 294elderlypatientswithdyslipidemiawereincluded.Allpa-tients were randomly divided into four groups：policosanol 20 mg group （ group A,n=64）; Policosanol 10mg group （group B,n=72）;atorvastatin 20mg group （group C,n=91）;policosanol 10mg ＋atorvastatin 20mg group（group D,n=62）.The following indexes were observed at 0d,12th week,24th week and 52th week： platelet counts,platelet aggregation rates,CECs,and carotid artery intima-media thickness.Results ADP induced platelet aggregation rate was decreased significantly in group A when compared with the baseline [（48.79 ±20.29）% vs.（40.37 ± 23.56）%],but AA induced platelet aggregation rate was not.Both AA and ADP induced Platelet aggregation rates had＆amp;nbsp;no significant changes in other groups.CECs,hs-CRP and Hcy levels were all decreased significantly at 52th week after treatment in each group.There was no statistical change of IMT in each group after treatment.Conclusions Besides lipid modulating effects,policosanol also had other effects such as improving endothelial functions and preventing pro-gression of atherosclerosis.

作者丁宇司全金陆蔷蔷徐昆王海军李开亮张帷

机构地区解放军总医院南楼心血管一科解放军总医院海南分院保健二科武警总医院信息科解放军九四二五九部队

出处《中国临床保健杂志》 CAS 2015年第5期468-471,共4页 Chinese Journal of Clinical Healthcare

关键词心血管疾病脂肪族醇类血小板聚集动脉粥样硬化老年人 Cardiovascular diseases Fatty alcohols Platelet aggregation Atherosclerosis Aged

分类号 R54 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献11

1Femandez S, Mas R, Gamez R, et al. A pharmacological surveillance study of the tolerability of policosanol in the elderly population [ J ]. Am J Geriatr Pharmacother,2004, 2(4) :219- 229.
2Castano G, M6s R, Arruzazabala ML, et al. Effects of policosanol and pravastatin on lipid profile, platelet aggrega- tion and endothelemia in older hypercholesterolemic pa- tients[J]. Int J Clin Pharmacol Res, 1999, 19 (4) : 105- 116.
3Men6ndez R, Amor AM, RodeiroI, et al. Policosanol modu- lates HMG-CoA reductase activity in cultured fibroblasts [ J]. Arch Med Res,2001,32( 1 ) :8-12.
4Mas R, Castano G, Femandzez J, et al. Long-term effects of plicosanol on obese patients with type hypercholesterol- emia[ J]. Asia Pac J Clinic Nutr,2004,13 (Supply) : 102 - S108.
5Janikula M. Policosanol: a new treatment for cardiovascu- lar disease? [J]. Altern Med Rev,2002,7(3) :203-217.
6Singh U, Dasu MR, Yancey PG, et al. Human C-reactive protein promotes oxidized low density lipoprotein uptake and matrix metal-loproteinase-9 release in Wistar rats [ J]. J Lipid Res,2008,49(5):1015-1023.
7韩建群,李炳蔚,苑晓晨,修瑞娟.循环内皮细胞:评价病理状态下血管内皮功能的重要生物标记物[J].中国微循环,2009,13(5):431-435. 被引量：8
8Takahashi H, Harker LA. Measurement of human endothe- lial cells in whole blood [ J ]. Thromb Res, 1983,31 (1) : 22-23.
9Sharif-Kazemi MB, Eshraghian K, Omrani GR, et al. Ho- moeysteine and coronary artery disease [ J ]. Angiology, 2006,57( 1 ) :9-14.
10Arenillas JF, Alvarez-Sabin J, Nolina CA, et al. C-reactive protein predicts further ischemic events in first-ever tran- sient ischemic attack or stroke patients with intracranial large-artery occlusive disease [ J]. Stroke,2003,34 (10) : 2463 -2468.

二级参考文献19

1王春玲,李宏伟,傅攀峰,张抒杨,高润霖,修瑞娟.冠心病患者循环内皮细胞与炎性相关因子的研究[J].中华心血管病杂志,2005,33(7):631-635. 被引量：17
2丁亚媛,杨志健,贾恩志,朱铁兵,王连生,陈波,曹克将,马文珠.C-反应蛋白含量与冠状动脉狭窄程度关系的研究[J].南京医科大学学报（自然科学版）,2006,26(6):441-444. 被引量：5
3李宏伟,王春玲,修瑞娟.人循环内皮细胞的分离和鉴定[J].基础医学与临床,2006,26(6):640-643. 被引量：12
4Mas R, Castano G, Femandzez J, et al. Long-term effects of plicosanol on obese patients with type Ⅱ hypercholes- terolemia[J]. Asia Pac J Clinic Nutr,2004, 13 (Supply): S102-S108.
5Menendez R,Marrero D,Mas R,et al. In vitro and in vivo study of octacosanol metabolism [J]. Arch Med Res, 2005,36(2) : 113-119.
6Castano G, Mas R, Arruzazabala ML, et al. Effects of pli- cosanol and pravastatin on lipid profile,platelet aggrega- tion and endothelemia in older hypercholesterolemie pa- tients [J]. Int J Clin Pharmacol Res, 1999,19 (4) : 105- 116.
7Menendez R, Amor AM, Rodeiro I, et al. Policosanol mod- ulates HMG-CoA reductase activity in cultured fibroblasts [J]. Arch Med Res,2001,32(1) :8-12.
8Noa M, Mds R, Lariot C,et al. Protective effect of poli- cosanol on endothelium and intimal thickness induced by forceps in rabbits[J]. J Med Food,2007,10(3) :452-459.
9Castalfo G,Femdndez L,Mas R,et al. Compairson of the effects of policosanol and atorvastatinon lipid profile and plate|etag egatiort inpatients with dyshpidaemia and type2 diabetes mellitus [J]. Clin Drug Investig,2003,23 (10) :639-650.
10Ridker PM,Paynter NP,Rifai N,et al. C-reactive protein and parental history improve global cardiovascular risk prediction : the reynolds risk score formen [ J ]. Circulation, 2008, 118 (22) : 2243-2251.